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Abstract 
This study intends to investigate the correlations of miR‑124a and miR‑30d with clinicopathological features of breast 
cancer (BC) patients with type 2 diabetes mellitus (T2DM). A total of 72 BC patients with T2DM (diabetic group) and 
144 BC patients without T2DM (non‑diabetic group) were enrolled in this study. Blood glucose was detected by 
glucose oxidase methods. Glycosylated hemoglobin (HbA1c) was measured by high performance liquid chromatog‑
raphy. Fasting insulin (FIns) was measured by chemiluminescent microparticle immunoassay. Automatic biochemi‑
cal analyzer was used to detect triglyceride, total cholesterol (TC), high‑density lipoprotein cholesterol (HDL‑C) and 
low‑density lipoprotein cholesterol (LDL‑C). Estradiol (E2) was detected by radioimmunoassay. Homeostasis model 
assessment was applied to assess the insulin resistance (HOMA‑IR) and β‑cell insulin secretion (HOMA‑IS). The expres‑
sions of miR124a and miR‑30d were measured by quantitative real‑time polymerase chain reaction (qRT‑PCR). There 
were significant differences in age, the ratio of menopause, body mass index (BMI), HDL‑C, TC, 2‑h plasma glucose 
(2hPG), FIns, HbA1c, HOMA‑IS and HOMA‑IR between the diabetic and non‑diabetic groups. The diabetic group had 
higher incidence of lymph node metastasis than non‑diabetic group. The miR‑124a expression was down‑regulated 
while the miR‑30d expression was up‑regulated in BC patients with T2DM. The correlation analysis showed that miR‑
124a expression was positively correlated with HDL‑C, while it was negatively correlated with age, HbA1c, LDL‑C and 
E2. However, the miR‑30d expression was negatively correlated with HDL‑C but positively correlated with age, HbA1c, 
LDL‑C and E2. In conclusion, miR‑124a and miR‑30d may be correlated with clinicopathological features of BC patients 
with T2DM. The miR‑124a and miR‑30d could serve as novel biomarkers for early diagnosis of BC in patients with 
T2DM.
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Background
Breast cancer (BC) is one of the most common malig-
nant neoplasms for females with 1.4 million new diagno-
ses a year worldwide, and is one of the leading causes of 
cancer-related death (Ban and Godellas 2014). Diabetes 
mellitus (DM), commonly referred to as diabetes, is a 
group of metabolic diseases with high blood sugar lev-
els over a prolonged period, and more than 95% of all 
DM cases is type 2 diabetes mellitus (T2DM) (American 
Diabetes 2013, 2014). It is reported that approximately 
7% of the people worldwide in the age between 20 and 
79 years is estimated to have DM in 2010 and the number 
is expected to rise by more than 50% in the next 20 years 
(Ginter and Simko 2012). Further, studies focused on 
the DM have demonstrated that DM was implicated in 
various cancers development, including pancreas cancer, 
colon cancer, liver cancer, esophagus cancer, endometrial 
cancer and BC (Chang et al. 2012; Pan et al. 2012; Shikata 
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et al. 2013; Wang et al. 2012). The relative risk for mortal-
ity of BC patients has been reported to be twofold greater 
in BC patients with DM than in those without DM (Liao 
et al. 2011), and the epidemiologic evidences showed that 
DM patients have a significant higher risk of BC and is 
closely associated with a poor prognosis of BC patients 
(Luo et  al. 2014; Oppong et  al. 2014). The BC patients 
with T2DM had been reported to be more likely to asso-
ciate with a higher incidence of lymph nodes and were 
at an advanced tumor stage, indicating a shorter survival 
time (He et al. 2015).
MicroRNAs (miRs) have been reported to be impli-
cated in various malignancies and involved in a variety of 
biological processes, including cell proliferation, differ-
entiation, apoptosis, and metastasis (Di Leva et al. 2014; 
Farazi et al. 2013). Acting as an abundant miR in the cen-
tral neuron system, miR-124a has been reported to be 
linked to the progression of various tumors and it may act 
as an important regulator of the transcriptional protein 
network in beta-cells responsible for regulating intracel-
lular signaling (Baroukh et  al. 2007; Chen et  al. 2013). 
Overexpression of miR-124a may inhibit the glucose-
stimulated insulin secretion and the altered expression 
of miR-124a may lead to beta-cell dysfunction in T2DM 
patients (Sebastiani et al. 2015). It has been reported that 
the methylation of miR-124a in adjacent normal mucosa 
may be correlated with the microsatellite instability of 
colorectal cancer (Deng et  al. 2011). Further, miR-30d 
regulates various physiological processes in normal tis-
sues or cancer cells, including development, metastasis, 
apoptosis, senescence, proliferation and differentiation 
(Bridge et  al. 2012; Zhao et  al. 2012). MiR-30d may be 
acted as a novel oncogene that may be implicated in the 
development of tumors and homeostasis, and may be 
served as a potential useful biomarker or drug target in 
human malignancies (Yang et  al. 2013). MiR-30d also 
plays a key role in activating glucose-induced insulin 
gene transcription and in avoiding beta-cell functions 
impaired by pro-inflammatory cytokines, which may act 
as a potential target for diabetes intervention (Zhao et al. 
2012).
Indeed, both miR-124a and miR-30d may partici-
pate in the development of BC and T2DM occurrence. 
In the present study, we investigated the expressions of 
miR-124a and miR-30d in BC patients with T2DM, and 
analyzed correlations of miR-124a and miR-30d with 
clinicopathological features of BC patients with T2DM.
Methods
Study subjects
Between January 2012 and January 2015, a total of 72 
patients diagnosed as BC with T2DM at Linyi People’s 
Hospital were enrolled as diabetic group in this study. 
According to the principle of 1:2, 144 patients diag-
nosed as BC without T2DM were randomly recruited 
as non-diabetic group using the random number table. 
The matching principle was the date of hospital visiting 
±1  month. All patients were confirmed as BC patients 
through the paraffin slide biopsy via the Department of 
pathology. The diagnosis of T2DM was as following: (1) 
patients were inquired of medical history (diagnosed 
as T2DM by secondary-and tertiary-level hospitals) by 
physician preoperative, medication history and the con-
dition of blood sugar monitoring; (2) fasting blood glu-
cose (FPG) ≥7.0 mmol/L at admission or random blood 
glucose levels ≥11.11  mmol/L, or the 2-h plasma glu-
cose (2hPG) from an oral glucose tolerance test (OGTT) 
≥11.1 mmol/L. Inclusion criteria: all patients had a com-
plete clinical data, including age, body mass index (BMI), 
family history, past medical history, menopausal status, 
tumor size, axillary lymph nodes, etc. Exclusion criteria: 
(1) BC patients with type 1 diabetes mellitus or second-
ary diabetes mellitus; (2) male BC patients; (3) patients 
with bilateral BC; (4) patients with carcinoma in  situ of 
breast or stage IV BC patients; (5) BC patients who had 
received neoadjuvant chemotherapy or estrogen therapy; 
(6) patients with incomplete clinical data; and (7) patients 
with nonstandard anticancer therapy. Among the 72 BC 
patients with T2DM, most of them were treated with 
oral hypoglycemic agents, but the patients with poor 
control of glucose level before operation were treated 
with insulin therapy after physician consultation from 
Department of endocrinology. All the patients enrolled 
in the study were underwent unilateral modified radical 
mastectomy, and received 6 cycles of TAC chemotherapy 
(Taxotere + Adriamycin + cyclophosphamide) postoper-
atively. The BC patients with lymph nodes were received 
postoperative radiotherapy, and the patients with hor-
mone-receptor-positive BC who received endocrine 
therapy. All patients were appropriately informed about 
this study and signed their informed consents forms. This 
study was conducted with the approval of the ethics com-
mittee of Linyi People’s Hospital, and the ethical approval 
for this study conformed to the standards of the Declara-
tion of Helsinki (Pn 2014).
The medical records were reviewed, including the 
admission number, name, age, BMI, menopausal status, 
history of diabetes, family history of BC, past medical 
history, diameter of tumor, pathological types, metastasis 
of axillary lymph nodes, tumor stage, histological grade, 
immunohistochemical markers (estrogen receptor: ER; 
progesterone receptor: PR; human epithelial growth fac-
tor receptor 2: Her-2, P-glyprotein: P-gp; topoisomerase 
II: Topo-II; glatocnine-S-tranferase-π: GST-π), surgical 
procedures, operation time, chemotherapy regimens and 
course of chemotherapy. All patients were followed up 
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after surgery. The tumor node metastasis (TNM) stages 
were classified in accordance with the grading standard 
published by the American Joint Committee on Can-
cer (AJCC) or Union for International Cancer Control 
(UICC) (Singletary et al. 2003).
Biochemical parameters
Blood glucose was determined by glucose oxidase 
method using a Roche glucometer (Accu-Chek Active, 
Roche Ltd., Germany). Glycosylated hemoglobin 
(HbA1c) was measured by high performance liquid chro-
matography (ADAMSTMA1c HA-8160, Japan). Fast-
ing insulin (FIns) was detected by chemiluminescent 
microparticle immunoassay (CMIA; Abbott i2000SR, 
USA). Triglyceride (TG), total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C) and low-den-
sity lipoprotein cholesterol (LDL-C) were detected 
by automatic biochemical analyzer (Roche Ltd., Ger-
many). Homeostasis model assessment was applied to 
assess insulin resistance and β-cell insulin secretion, i.e. 
HOMA-IR = (FPG × FIns)/22.5. HOMA of β-cell insulin 
secretion (HOMA-IS) = 20 × FIns/(FPG − 3.5).
The last menstrual periods of patients were recorded, 
and the concentration of E2 in the follicular phase at 
2–4  days after menstruation was detected. The E2 level 
in the blood serum was measured by radioimmunoassay 
(radio-immunity kits, Depp Biological Technology and 
Medical Products Co. Ltd, Tianjin, China), with intra-
assay coefficient of variance (CV) 7.96% and inter-assay 
CV 9.22%.
Quantitative real‑time polymerase chain reaction 
(qRT‑PCR)
Blood sample from the each patient after 12  h fasting 
was collected in the next morning, and was centrifuged 
following the instructions of RNA extraction kit. Total 
RNA was extracted by a miRNeasy Mini Kit (Qiagen 
Company, Hilden, Germany). RNA samples (5 μL) were 
diluted 20 times in RNA-free ultrapure water. The con-
centration and quality of RNA were determined by the 
ultraviolet absorbance at 260 and 280 nm (optical density, 
OD; OD260/OD280 ratio) using an ultraviolet spectro-
photometer. The OD260/OD280 ratio between 1.7 and 
2.1 indicated that the RNA had high purity, which could 
meet the requirements of further research processes. The 
cDNA template was generated by reverse transcription 
in a PCR amplifier. The qRT-PCR was conducted by ABI 
7500 quantitative PCR System (Life Technologies, USA). 
The reaction condition was 40 cycles of denaturation at 
95 °C for 10 min, denaturation at 95 °C for 10 s, anneal-
ing at 60 °C for 20 s and extension at 72 °C for 34 s. The 
primers were synthesized by Sangon Biotech (Shanghai, 
China), as illustrated in Table 1. U6 snRNA was used as 
an internal control. The cycle number at threshold (Ct 
value) was used to calculate the relative expressions of 
miR124a and miR30d. The results were presented as 
fold change, and calculated using the 2−ΔΔCT method 
(Livak and Schmittgen 2001), with the formula as: 
ΔΔCT = ΔCtdiabetic group –ΔCtnon-diabetic group, ΔCt = CtmiR 
– CtU6. The experiments were totally repeated for 3 
times.
Statistical analysis
SPSS19.0 was used to conduct the statistical analysis. 
Measurement data were expressed as mean  ±  stand-
ard deviation (SD). Variance homogeneity test was used 
before analysis, and One-Way ANOVA analysis was used 
for multiple group comparisons. The least significant 
difference (LSD)-t test or Chi square test was used in 
pairwise comparison of averages among groups. The rela-
tionships between the expressions of miR-124a and miR-
30d and clinicopathological features and biochemical 
parameters were analyzed by Pearson correlation analysis 
and linear regression analysis. P  <  0.05 showed statisti-
cally significant.
Results
Comparisons of clinical features and biochemical 
parameters between the diabetic group and non‑diabetic 
group
The mean age of patients in the diabetic group 
was 52.72  ±  6.23  years, and the mean BMI was 
24.68 ± 4.74 kg/m2. In the diabetic group, 33.61% cases 
were premenopausal patients and 76.39% cases were 
postmenopausal patients. The mean age of patients in 
the non-diabetic group was 50.08 ±  4.76  years and the 
mean BMI was 23.21 ± 3.25 kg/m2. Of the 144 patients 
in the non-diabetic group, 44.44% cases were premeno-
pausal patients and 55.56% cases were postmenopausal 
patients. There were significant differences on age, the 
ratio of menopause and BMI between the two groups 
(age: P  <  0.001; ratio of menopause; P  =  0.003; BMI: 
P = 0.008). Further, significant differences were observed 
in HDL-C, LDL-C, TC, FPG, 2hPG, FIns, HbA1c, 
Table 1 The primer sequences for qRT-PCR
qRT-PCR quantitative real-time polymerase chain reaction
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HOMA-IS, HOMA-IR and E2 between diabetic group 
and non-diabetic group (all P < 0.05). The family history 
of BC, underlying diseases, systolic blood pressure (SBP), 
diastolic blood pressure (DBP) or TG had no significant 
differences between the two groups (all P > 0.05), as illus-
trated in Table 2.
Comparisons of pathological features between the 
diabetic group and non‑diabetic group
The comparisons of pathological features indicated that 
diabetic group had higher incidence of lymph node 
metastasis than non-diabetic group (P  <  0.001). How-
ever, there were no significant differences in diameter of 
tumor, ratio of axillary lymph nodes, pathological types, 
tumor stage, histological grade, ER, PR, Her-2, P-gp, 
Topo-II and Gst-π (all P > 0.05) (Table 3).
Expressions of miR‑124a and miR‑30d in the diabetic 
group and non‑diabetic group
The expressions of miR-124a and miR-30d in the diabetic 
group and non-diabetic group were detected by qRT-
PCR. The results showed that the miR-124a expression in 
the diabetic group was 0.42 fold of that in the non-diabetic 
group, as the relative expression of miR-124a in the non-
diabetic group was defined as 1 (P < 0.05). However, the 
miR-30d expression in the diabetic group was 1.64 fold 
of that in the non-diabetic group, as the relative expres-
sion of miR-30d in the non-diabetic group was defined as 
1 (P < 0.05) (Fig. 1). These results suggested that miR-124a 
may act as an anti-oncogene while the miR-30d may act as 
an oncogene in the development of BC with T2DM.
Correlations of miR‑124a and miR‑30d 
with clinicopathological features in BC patients with T2DM
The Pearson correlation analysis was conducted to explore 
the correlations between miRs124a/30d and age, BMI, 
FPG, HbA1c, 2hPG, TC, HDL-C and LDL-C. The corre-
lation analysis showed that the miR-124a expression was 
positively associated with HDL-C (P < 0.001), while it was 
negatively associated with age, HbA1c, LDL-C and E2 (all 
P < 0.05). No significant differences were observed between 
the miR-124a expression and BMI, FPG, 2hPG or TC (all 
P > 0.05). Further, the miR-30d expression was negatively 
correlated with HDL-C (P < 0.001), while it was positively 
correlated with age, HbA1c, LDL-C and E2 (all P  <  0.05). 
There were no significant differences between the miR-
30d expression and BMI, FPG, 2hPG or TC (all P > 0.05), 
as shown in Table 4. Linear regression analysis showed that 
the HbA1c, LDL-C, HDL-C and E2 were independent fac-
tors for expressions of miR-124a and miR-30d (Tables 5, 6).
Table 2 Comparisons of clinical features and biochemical parameters between diabetic group and non-diabetic group
Comparisons on family history of BC, underlying diseases and the ratio of menopause between the two groups were measured by χ2 test; BMI, weight (kg)/height 
(m2); Normal BMI, 18.5–22.9 kg/m2
Diabetic group, breast cancer patients with type 2 diabetes mellitus; Non-diabetic group, breast cancer patients without type 2 diabetes mellitus
BC breast cancer, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density 
lipoprotein cholesterol, TG triglyceride, TC total cholesterol, FPG fasting blood glucose, 2hPG 2-hour postprandial blood glucose, HbA1c glycosylated hemoglobin, FIns 
fasting insulin, HOMA-IR homeostasis model assessment of insulin resistance, HOMA-IS HOMA of β-cell insulin secretion, E2 estradiol
Diabetic group (n = 72) Non‑diabetic group (n = 144) t/χ2 P value
Age (years) 52.72 ± 6.23 50.08 ± 4.76 3.113 <0.001
Family history of BC 5.56% (4) 4.17% (6) 0.458 0.647
Underlying diseases 19.44% (14) 20.83% (30) 0.057 0.811
Ratio of menopause 76.39% (55) 55.56% (80) 8.889 0.003
BMI (Kg/m2) 24.68 ± 4.74 23.21 ± 3.25 2.673 0.008
SBP (mmHg) 124.68 ± 10.35 125.36 ± 11.23 0.430 0.667
DBP (mmHg) 78.36 ± 7.93 80.57 ± 8.54 1.835 0.068
HDL‑C (mmol/L) 1.21 ± 0.32 1.31 ± 0.36 1.995 0.047
LDL‑C (mmol/L) 3.85 ± 0.74 3.12 ± 0.65 7.425 <0.001
TG (mmol/L) 1.32 ± 0.35 1.41 ± 0.41 1.594 0.112
TC (mmol/L) 4.45 ± 0.87 3.64 ± 0.68 7.498 <0.0001
FPG (mmol/L) 8.32 ± 0.73 5.27 ± 0.43 38.56 <0.001
2hPG (mmol/L) 14.68 ± 1.02 5.58 ± 0.47 89.810 <0.001
HbA1c (%) 10.57 ± 2.11 5.64 ± 1.57 19.320 <0.001
FIns (uU/mL) 10.14 ± 3.25 5.33 ± 1.87 6.954 <0.001
HOMA‑IS 42.84 ± 14.53 60.50 ± 16.29 7.779 <0.001
HOMA‑IR 3.75 ± 1.25 1.27 ± 0.50 20.750 <0.001
E2 (pg/mL) 50.20 ± 11.40 23.66 ± 8.63 19.080 <0.001
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Discussion
In the present study, we aimed to explore the correlations 
of miR-124a and miR-30d with BC patients with T2DM. 
We explore the correlations of miR-124a and miR-30d 
with the clinicopathological features of BC patients with 
T2DM. We found that the miR-124a expression was 
positively associated with HDL-C, while miR-30d expres-
sion was negatively correlated with HDL-C. Moreover, 
Table 3 Comparisons of pathological characteristics between diabetic group and non-diabetic group
Diabetic group, breast cancer patients with type 2 diabetes mellitus; non-Diabetic group, breast cancer patients without type 2 diabetes mellitus
WHO World Health Organization, ER estrogen receptor, PR progesterone receptor, Her-2 human epithelial growth factor receptor 2, P-gp P-glyprotein, Topo-II 
topoisomerase II, Gst-π glatocnine-S-tranferase-π
Characteristic Diabetic group (n = 72) [%] Non‑diabetic group (n = 144) [%] χ2 P value
T stage
 T1 16 (22.2) 36 (25.0) 0.809 0.667
 T2 35 (48.6) 74 (51.4)
 T3 21 (29.2) 34 (23.6)
Axillary lymph nodes
 Positive 45 (62.5) 75 (52.1) 2.109 0.146
 Negative 27 (37.5) 69 (47.9)
Pathological types
 Invasive ductal carcinoma 66 (91.7) 136 (94.4) 0.890 0.828
 Invasive lobular carcinoma 3 (4.2) 3 (2.1)
 Invasive papilloma 2 (2.8) 3 (2.1)
 Mucinous adenocarcinoma 1 (1.4) 2 (1.4)
Tumor stage
 I 4 (5.6) 19 (13.2) 2.966 0.227
 II 27 (37.5) 51 (35.4)
 III 41 (56.9) 74 (51.4)
Histological grade
 WHO I 5 (6.9) 9 (6.2) 2.099 0.350
 WHO II 42 (58.3) 98 (68.1)
 WHO III 25 (34.7) 37 (25.7)
Lymph node metastasis
 Positive 45 (62.5) 55 (38.2) 11.410 <0.001
 Negative 27 (37.5) 89 (61.8)
ER
 Positive 42 (58.3) 88 (61.1) 0.155 0.694
 Negative 30 (41.7) 56 (38.9)
PR
 Positive 40 (55.6) 91 (63.2) 1.174 0.279
 Negative 32 (44.4) 53 (36.8)
Her‑2
 Positive 25 (34.7) 66 (458) 2.431 0.119
 Negative 47 (65.3) 78 (54.2)
P‑gp
 Positive 60 (83.3) 121 (84.0) 0.017 0.896
 Negative 12 (16.7) 23 (16.0)
Topo‑II
 Positive 64 (88.9) 132 (91.7) 0.441 0.507
 Negative 8 (11.1) 12 (8.3)
Gst‑π
 Positive 39 (54.2) 70 (48.6) 0.593 0.441
 Negative 33 (45.8) 74 (51.4)
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miR-124a expression was negatively associated with age, 
HbA1c, LDL-C and E2, while miR-30d expression was 
positively correlated with age, HbA1c, LDL-C and E2. 
These results indicated that the levels of HbA1c, LDL-C, 
HDL-C and E2 were correlated with the expressions of 
miR-124a and miR-30d, and may be acted as independent 
factors for expressions of miR-124a and miR-30d.
It was well-known that T2DM is characterized by insu-
lin resistance and impaired insulin secretion caused by 
insufficiency of pancreatic beta-cells (Mizokami-Stout 
et al. 2012; Okuno et al. 2013). Additionally, HbA1c may 
capture the glucose exposure that may relevant to can-
cer risk and higher HbA1c level may be correlated with 
a higher risk of cancer incidence and cancer-related mor-
tality (Joshu et al. 2012; Li et al. 2014). Estrogen has also 
been reported to be involved in the pathogenesis and 
disease progression of BC and down-regulated estrogen 
level could be a potential management for most patients 
with estrogen responsive tumors (Su et al. 2013). Further, 
the estrogen may promote cell proliferation and inhibits 
cell apoptosis by modulating gene transcription in estro-
gen-dependent tumors, and the high serum E2 levels may 
be associated with specific gene expression patterns in 
BC tissues (Chalasani et al. 2014; Kim et al. 2013).
Our study results have revealed that the miR-124a 
expression in BC patients with T2DM was signifi-
cantly lower than that in BC patients without T2DM. 
The tumor-related miRs function as tumor suppressors 
or oncogenes and regulate various aspects of carcino-
genesis, including cell proliferation, cell-cycle control, 


























































Fig. 1 Expressions of miR‑124a and miR‑30d in the diabetic group and non‑diabetic group. Note a miR‑124a expression in the diabetic and non‑
diabetic groups; b miR‑30d expression in the diabetic and non‑diabetic groups; *P < 0.05; **P < 0.05; miR‑124, microRNA‑124a; miR‑30d, microRNA‑
30d
Table 4 Correlation analysis of  miR-124a and  miR-30d 
with  various biochemical parameters in  BC patients 
with T2DM
BMI body mass index, HDL-C high-density lipoprotein cholesterol, LDL-C low-
density lipoprotein cholesterol, TC total cholesterol, FPG fasting blood glucose, 
2hPG 2-hour postprandial blood glucose, HbA1c glycosylated hemoglobin, FIns 
fasting insulin, HOMA-IR homeostasis model assessment of insulin resistance, 
HOMA-IS HOMA of β-cell insulin secretion, E2 estradiol
Index miR‑124a miR‑30d
r value P value r value P value
Age (years) −0.353 0.002 0.333 0.004
Ratio of menopause −0.049 0.685 0.134 0.262
BMI (Kg/m2) −0.172 0.148 0.218 0.066
HDL‑C (mmol/L) 0.698 <0.001 −0.731 <0.001
LDL‑C (mmol/L) −0.754 <0.001 0.786 <0.001
TC (mmol/L) −0.071 0.554 0.069 0.564
FPG (mmol/L) −0.115 0.337 0.097 0.419
2hPG (mmol/L) −0.097 0.418 0.091 0.447
HbA1c (%) −0.443 <0.001 0.496 <0.001
FIns (uU/mL) −0.139 0.246 0.128 0.284
HOMA‑IS −0.085 0.478 0.096 0.421
HOMA‑IR −0.160 0.179 0.139 0.243
E2 (pg/mL) −0.763 <0.001 0.765 <0.001
Table 5 Linear regression analysis of  the factors for  miR-
124a expression
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; HbA1c, glycosylated hemoglobin; E2, estradiol; B: regression 






B Std. error Beta
(Constant) 0.866 0.108 8.025 <0.001
LDL‑C −0.045 0.015 −0.275 −2.888 0.005
Age −0.002 0.001 −0.125 −1.977 0.052
HDL‑C 0.098 0.030 0.263 3.306 0.002
HbA1c −0.008 0.004 −0.145 −2.222 0.030
E2 −0.004 0.001 −0.341 −3.744 <0.001
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2013; Profumo and Gandellini 2013). MiR-124a is mainly 
expressed in brains and pancreas, and the over expres-
sion of miR-124a in pancreatic β-cells can improve the 
insulin secretion, but it can reduce the insulin secretion 
stimulated by high concentration of glucose (Baroukh 
et al. 2007). The expression and mechanisms of miR-124 
have also been investigated in BC, and Han et al. (2013) 
have found that miR-124 may play a key role in inhibit-
ing the invasion and metastasis of BC cells, probably by 
directly targeting CD151 genes. MiR-124a overexpres-
sion could down-regulate FoxA2 expression, which could 
bind with PDX1 and ISL1 in the islet amyloid polypeptide 
(IAPP) promoter, thus decreasing the IAPP levels and 
inhibiting the apoptosis of β-cells (Jing et al. 2014). Fur-
ther, Li et al. (2013) have demonstrated that the expres-
sion of miR-124 was down-regulated in BC patients, and 
the miR-124 might be acted as a tumor suppressor in BC 
through the regulation of FLOT1 gene. The study per-
formed by Dong et al. (2015) has revealed that decreased 
expression of miR-124 may be associated with advanced 
TNM stage, lymph node metastasis and poorer patho-
logical differentiation, implying that down-regulation of 
miR-124 may be an independent unfavorable prognostic 
factor for BC patients. Further, high levels of insulin are 
mitogenic for BC cells, and overexpressed insulin recep-
tors are often found in BC patients (Kaplan et al. 2012). 
Hyperexpression of miR-124a may be impaired glucose-
stimulated insulin secretion, and the silencing of the 
miR-124a resulted in increased expression of target genes 
for beta-cell function, indicating that an altered miR-124a 
expression may lead to beta-cell dysfunction in T2DM 
(Sebastiani et al. 2015). Meanwhile, insulin release from 
pancreatic beta-cells acts an important role in blood glu-
cose homeostasis, and the pancreatic development is a 
complex sequential expression of a gamut of transcrip-
tion factors. Foxa2 deficiency may result in excessive 
insulin release in response to amino acids and complete 
loss of glucose-stimulated insulin secretion (Gao et  al. 
2010; Lantz et al. 2004). Baroukh et al. (2007) have dem-
onstrated that miR-124a may be implicated in the cell 
differentiation process of beta-cells, and the miR-124a 
may play as a regulator of a key transcriptional protein 
network in beta-cells responsible for modulating intra-
cellular signaling by targeting Foxa2 gene. In this regard, 
we suspected that the lower expression of miR-124a may 
be involved in the development and progression of BC 
patients combined with T2DM.
In this study, we found that the miR-30d expres-
sion in BC patients with T2DM was significantly higher 
than that in BC patients without T2DM. Meanwhile, we 
found that miR-30d expression was positively associated 
with the levels of HbA1c, LDL-C and E2, and the levels 
of HbA1c, LDL-C and E2 may be acted as independent 
factors for expression of miR-30d. Recent evidence has 
suggested that miR-30d may be acted as a novel antion-
cogene (Li et al. 2012; Lu et al. 2009; Zhao et al. 2012). In 
patients with diabetes or with high level of glucose, miR-
30d could regulate Map4k4 expression to increase the 
levels of insulin transcription factors, thus promoting the 
insulin secretion and reducing TNF-α-induced transcrip-
tion and production of insulin genes (Tang et al. 2009). It 
has been reported that miR-30d may suppress renal car-
cinoma cell proliferation by regulating cyclin E2 expres-
sion at a post-transcriptional level (Yu et al. 2014). Tang 
et al. (2009) have found that the up-regulated expression 
of miR-30d by glucose may increase the insulin gene 
expression, while the inhibition of miR-30d may abolish 
glucose-stimulated insulin gene transcription, which may 
be a negative regulator of insulin gene expression.
Conclusion
MiR-124a and miR-30d may be correlated with clinico-
pathological features of BC patients with T2DM. The 
miR-124a and miR-30d could serve as novel biomarkers 
for early diagnosis of BC in patients with T2DM. How-
ever, the exact mechanism of miR-124a and miR-30d in 
the progression of BC combined with T2DM was still 
unclear. Further study based on the target genes of miR-
124a or miR-30d need to be conducted to explore the 
underlying mechanisms of miR-124a and miR-30d on the 
development of BC combined with T2DM.
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